Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05086276 · ClinicalTrials.gov registry record · Phase 2

FX-322 in Adults With Acquired Sensorineural Hearing Loss

A Phase 2 study of Hearing Loss, Sensorineural and Noise-induced Hearing Loss, sponsored by Frequency Therapeutics.

Completed
Registry status
Phase 2
Development phase
142
Enrollment target
20
Study locations

NCT05086276 is a Phase 2 study of Hearing Loss, Sensorineural and Noise-induced Hearing Loss that has completed, run by Frequency Therapeutics. The registered enrollment target is 142 participants, below the 779-participant average among 20 other Hearing Loss, Sensorineural trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05086276, a Phase 2 study of Hearing Loss, Sensorineural and Noise-induced Hearing Loss, has completed, sponsored by Frequency Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
142 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).

Conditions Studied

Hearing Loss, Sensorineural Noise-induced Hearing Loss Sudden Hearing Loss

Interventions

  • DRUG Placebo
  • DRUG FX-322

Study Locations (20)

New York

  • Clinical Trial Site - Albany
  • Clinical Trial Site - Amherst
  • Clinical Trial Site - New York

South Carolina

  • Clinical Trial Site - Charleston
  • Clinical Trial Site - Orangeburg
  • Clinical Trial Site - Spartanburg

California

  • Clinical Trial Site - Fresno
  • Clinical Trial Site - Torrance

Florida

  • Clinical Trial Site - Sarasota
  • Clinical Trial Site - Tampa

Texas

  • Clinical Trial Site - Dallas
  • Clinical Trial Site - Fort Worth

Arizona

  • Clinical Trial Site - Tucson

Colorado

  • Clinical Trial Site - Colorado Springs

Louisiana

  • Clinical Trial Site - Marrero

Trial Details

FieldValue
Enrollment Target 142 participants
Start Date 2021-10-12
Est. Completion 2022-12-30
Phase Phase 2

Sponsor

Frequency Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05086276

The ClinicalTrials.gov registry entry for NCT05086276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 779-participant average among 20 other Hearing Loss, Sensorineural trials with a reported enrollment target (82% lower). The listed sponsor is Frequency Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hearing Loss, Sensorineural appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05086276 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, South Carolina, California.

Frequently Asked Questions

What is clinical trial NCT05086276 about?

NCT05086276 is a clinical study titled "FX-322 in Adults With Acquired Sensorineural Hearing Loss". This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).

What is the current status of trial NCT05086276?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2021-10-12. Estimated completion is 2022-12-30.

What conditions does trial NCT05086276 study?

This clinical trial studies the following conditions: Hearing Loss, Sensorineural, Noise-induced Hearing Loss, Sudden Hearing Loss.

What interventions are being tested in trial NCT05086276?

The interventions under investigation include: Placebo (DRUG), FX-322 (DRUG).

Who is sponsoring clinical trial NCT05086276?

This trial is sponsored by Frequency Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05086276 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hearing Loss, Sensorineural

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hearing Loss, Sensorineural

All registered trials for this condition

Noise-induced Hearing Loss

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.